In this study, we show that the promoter hypermethylation of miR-195/497 cluster causes their down-regulation in breast cancer. The Levels of miR-195/497 expression are inversely correlated with tumor malignancy, and Raf-1 is identified as a direct target of both miRNAs. Our data imply that both miR-195 and miR-497 may be potential interest as therapeutic and diagnostic targets in breast cancer. Abstract Purpose: To investigate expression, regulation, potential role and targets of miR-195 and miR-497 in breast cancer. Experimental design: The expression patterns of miR-195 and miR-497 were initially examined in breast cancer tissues and cell lines by Northern blotting and quantitative real-time PCR. Combined bisulfite restriction analysis and bisulfite sequencing were carried out to study the DNA methylation status of miR-195 and miR-497 genes. Breast cancer cells stably expressing miR-195 and miR-497 were established to study their role and targets. Finally, normal, fibroadenoma and breast cancer tissues were employed to analyze the correlation between miR-195/497 levels and malignant stages of breast tumor tissues. Results: MiR-195 and miR-497 were significantly down-regulated in breast cancer. The methylation state of CpG islands upstream of the miR-195/497 gene was found to be responsible for the down-regulation of both miRNAs. Forced expression of miR-195 or miR-497 suppressed breast cancer cell proliferation and invasion. Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497. miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer.
Introduction
MicroRNAs (miRNA) are a class of highly conserved, small noncoding RNAs, which regulate gene expression in a variety of eukaryotic organisms and execute pivotal roles in physiological and pathological processes including development, differentiation, metabolism, immunity, cell proliferation and apoptosis (1) (2) (3) . In general, these single-stranded miRNAs show a trend toward multiple targeting sites in the coding sequence (CDS) regions or the 3' untranslated (3'UTR) regions of their target messenger RNAs (mRNAs) and cause translational repression or mRNA cleavage (4) . There is growing evidence that differential expressions of miRNAs are associated with tumor types and cancer development (5) .
Breast cancer is one of the leading causes of cancer death in women worldwide (6) . miRNAs, such as miR-21, miR-27a, miR-17, miR-155, miR-10b, miR-125b and miR-145, are found to be dysregulated and serve as oncogenic agent or tumor suppressor in breast cancer (6) (7) (8) (9) (10) (11) . It has been known that these tine molecules are involved in tumor cell proliferation, migration, invasiveness and metastasis. Recently, blood-based miRNA profiling studies demonstrate that systemic miR-195 levels are increased before surgery and decreased after surgery in breast cancer patients (12) . Interestingly, miR-497 has been found to be one of most prominently down-regulated miRNAs in male breast cancer (13) .
As miR-195/497 is a highly conserved miRNA cluster located at Chromosome 17p13.1 (6) , it would be interesting to simultaneously the roles of miR-497 in breast cancer.
Accumulating evidence also demonstrates that genetic and epigenetic alterations cause the dysregulation of subsets of miRNAs (14, 15) . Among them, promoter
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Author Manuscript Published OnlineFirst on February 24, 2011; DOI: 10.1158/1078-0432.CCR-10-1800 6 hypermethylation is known for silencing the specific miRNA expression to be involved in tumorigenesis (15) . Mammalian DNA is predominantly methylated at the C-5-position of complimentary CpG bp by DNA methyltransferases (16) . The aberrations of this epigenetic modification may lead to various diseases including cancer (15, 17) . For miRNA expression, DNA methylation of CpG islands was found to be present in the promoter region of miRNAs with tumor suppressor features in human cancer such as miR-127, miR-124a, miR-1, as well as miR-148a and miR-34b (18) (19) (20) (21) . Thus, such DNA methylation might also play a role in tumorigenesis. The objective of the present study was to reveal the roles of miR-195 and miR-497 in breast cancer. 
Materials and Methods

Human tissue samples
Human breast tumor samples and normal tissues were obtained from Peking Union Medical College Hospital and Shanghai Huashan hospital. All participants provided written informed consent following institutional review board approval at the participating hospitals. Tissue samples were collected and frozen in liquid nitrogen. These tissues were prepared in the hospital biorepository, and clinical annotation is available though a database.
Cases were classified and selected based on diagnosis using the CoPath Anatomic
Pathology system, and no information regulated by HIPPA was included in the study, which qualifies for the status of NIH Exemption #4. supplemented with 10% fetal bovine serum (FBS). MCF7 cells were maintained in MEM supplemented with 10% FBS, and 0.01 mg/ml bovine insulin. Total RNAs were extracted from tissues and cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA).
Cell culture and RNA preparation
Combined bisulfite restriction analysis and bisulfite sequencing.
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Author Manuscript Published OnlineFirst on February 24, 2011; DOI: 10.1158/1078-0432.CCR-10-1800 8 The University of California Santa Cruz (UCSC) database was used to identify CpG islands (CGI) spanning miR-195 and miR-497 genes. Genomic DNA was isolated using Universal Genomic DNA Extraction Kit Ver.3.0 (Takara, Shiga, Japan), and bisulfite conversion was performed using EZ DNA Methylation-Gold Kit™ (Zymo Research, Orange, CA).
Bisulfite-converted genomic DNA that converts only unmethylated cytosines to uracils, was amplified with specific primers. The purified PCR fragments were cloned into a TAACTCCCTCAATCTCTTATTCTT.
5-Aza-dC treatment and precursor transfection
ZR-75-30 cells were seeded 24 h prior to treatment with 5 µM 5-aza-2'-deoxycytidine Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on February 24, 2011; DOI: 10.1158/1078-0432.CCR-10-1800 10 (Takara,) 1.5 μmol/L forward primer, and 0.7 μmol/L reverse primer. The reactions were incubated in a 96-well plate at 95°C for 10 sec, followed by 40 cycles of 95°C for 5 sec, and 60°C for 30 sec. The 2 -⊿⊿ Ct method for relative quantification of gene expression was used to determine miRNA expression levels. Each sample was analyzed in triplicate, and U6 RNA was used to normalize the miRNA levels.
Western blot analysis.
For each sample, 25 μg of total protein extracts were separated on SDS-PAGE gels, and transferred to PVDF membrane. All the primary antibodies were incubated overnight at 4°C, followed by the incubation with AP-conjugated goat anti-rabbit secondary antibody and detection with BCIP/NBT (Amresco, Solon, OH). Bands were quantified with Labworks Instrument software (UVP LLC, Upland, CA).
Soft agar colony-formation assays
MCF7 and ZR-75-30 cells were transfected with miR-195, miR-497, or negative control precursor miRNAs. After 24 h of transfection, cells were suspended in complete medium containing 0.35% agar, and overlaid on 0.6% agar in 6-well plates (2× 10 3 cells/well). Each assay was performed in triplicates. The plates were maintained for up to 2 weeks. The number of colonies (> 50 μm in diameter) was counted under a microscopic field at 10× magnification.
Fluorescence-activated cell sorting (FACS) cell cycle analysis.
Author Manuscript Published OnlineFirst on February 24, 2011; DOI: 10.1158/1078-0432.CCR-10-1800 MCF7 and ZR-75-30 cells were seeded at 30% confluence in 12-well plate 24 h before transfection. Cells were treated with nocodazole for 16-20 h after the transfection of miR-195，miR-497, or negative control precursor at 100 nM; and fixed in 70% ethanol at 4°C for 24 h. Fixed cells were then washed once with PBS, resuspended in 500 ml PBS containing10 mg/ml propidium iodide and 50 mg/ml RNase, and incubated for 30 min at room temperature. The cells were then analyzed with Fluorescent-Activated Cell Sorter (BD FACSaria cell sorter, BD Bioscences, San Jose, CA, USA).
Lentivirus preparation, titration and infection
HEK293T cells were seeded in 10 cm plate at 6×10 6 The Mann-Whitney test was used to compare depot-specific differences between cancer tissues and normal controls. The results were considered statistically significant at p< 0.05. 
Results
MiR
DNA methylation is responsible for miR-195 and miR-497 down-regulation.
We sequentially examined the methylation status of CpG islands in human breast cancer Figure 3B ). To understand the potential mechanism of miR-195, miR-497 in inhibiting these biological effects, we found that miR-195 and miR-497 overexpression for induced cell cycle G1 arrest 48 h after transfection ( Figure 3C ), and 24 h and 36 h after transfection ( Supplementary Figure 1) .
MiR-195 and miR-497 directly target Raf-1. To further understand molecular mechanism of miR-195 and miR-497 in inhibiting breast cancer cells, we searched for potential targets of miR-195 and miR-497 by the KeyTar miRNA target prediction algorithm that is based on sequences and real physiological situation. This algorithm suggested that Raf-1 is a novel direct target of both miR195 and miR-497 ( Figure 4B ).
The potential sites of miR195 and miR-497 in Raf-1 3'UTR were even more conserved than those in Ccnd1 3'UTR, a known target of miR-195 and miR-497. Luciferase assays showed that miR-195 and miR-497 significantly reduced the activity of the Raf-1 gene reporter, but not of the mutated gene reporter ( Figure 4C ). Western blot analysis of Raf-1 and Ccnd1 in ZR-75-30 and MCF7 cell lines showed that miR-195 or miR-497 transfection inhibited Raf-1 and Ccnd1 expression and ERK1/2 phosphorylation ( Figures 4D-4E ). To confirm the data further, we subsequently established stable-expression of miR-195 and miR-497 breast cancer cells by lentivirus transfection (Figure 4F) . Similarly, we found that miR-195 and miR-497 inhibited cell growth and survival (data not shown), and led to significant down-regulation of both Raf-1 and Ccnd1 in vitro ( Figure 4G ). The results further demonstrate that Raf-1 is a novel target of miR-195 and miR-497 in different experimental systems.
MiR-195 and miR-497 levels correlate inversely with malignancy of human
Author Manuscript Published OnlineFirst on February 24, 2011; DOI: 10.1158/1078-0432.CCR-10-1800 breast tumors. We also investigated the relationship between the expression levels of miR-195 and miR-497 and the malignant stages of human breast tumors. As shown in Figure 5A , miR-195 and miR-497 levels were significantly down-regulated in malignant tumors (n=71, Stage I-III) when compared to those in the normal tissues (P<0.0001), and to those in the benign tumors, known as fibroadnoma (P<0.05). No significant difference existed between normal and benign tumor. Such data suggested that levels of miR-195 and miR-497 are inversely associated with malignancy of human breast cancer. But there were no significant differences between each stage of breast cancer (P>0.05), indicating that miR-195 and miR-497 could not be used in staging of malignant breast tumors. In addition, malignant breast tumors showed much higher expression levels of Raf-1 and Erk1/2 when compared to the normal tissues ( Figure 5B) . Thus, the expression levels of Raf-1 are inversely correlated with expression levels of miR-195 and miR-497 in human cancer tissues. In addition, we analyzed the association between miR-195/497 and hormone receptors. No significant difference of miR-195/497 expression was found between estrogen receptor (ER) positive (n=45) versus ER negative (n=26) breast cancers. There was no significant difference of the two miRNAs between progesterone receptor (PR) positive and PR negative tumors (n=40 vs 31, P>0.05).
Discussion
In this study, miR-195 and miR-497 were found to be significantly down-regulated in breast cancer tissues and cell lines. MiR-195 was initially reported to be up-regulated in cardiac hypertrophy, and its overexpression led to pathological heart growth and heart Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on February 24, 2011; DOI: 10.1158/1078-0432.CCR-10-1800 failure in transgenic mice (22) . Recently, miR-195 was found to be down-regulated in a variety of cancers, including gastric cancer, liver cancer, bladder cancer, and adrenocortical cancer (23) (24) (25) (26) . Introduction of miR-195 markedly suppressed colony formation in vitro and tumor development in nude mice (24) . MiR-497 expression was found to be down-regulated in different cancers, such as primary peritoneal carcinoma, gastric cancer and breast cancer (23, 27) . However, the role of miR-497 in human cancer is not clear yet.
Our data suggested that both miR-195 and miR-497 were significantly down-regulated in breast cancer, and that they were regulated by a common mechanism of CpG methylation upstream of miR-195 and miR-497 promoters. Recent studies showed that certain miRNA genes such as miR-1, miR-127, miR-148a, and miR-34b/c contain CpGs that are susceptible to DNA methylation for decreasing their expression (18, 20, 21) . To understand whether CpG methylation was responsible for downregulation of miR-195 and miR-497, we found that DNA demethylating agent treatment restored the expression of miR-195 and miR-497 in breast cancer cells, suggesting that DNA methylation in CpG inucleotides upstream of miR-195 and miR-497 promoters has a functional role to decrease their expression. Other than DNA methylation, p53 inactivation or genetic deletion could lead to miRNA deregulation (28, 29) . In chronic lymphocytic leukemia patients, chromosome 17p deletion may influence a set of miRNAs, such as miR-21 and miR-34a (30, 31) .
In addition, forced expression of miR-195 and miR-497 had similar effect to suppress breast cancer cell proliferation, blocked cell cycle G1 progression, and induced apoptosis.
Such results suggest that miR-195 and miR-497 have similar effects to play a tumor-suppressor role in breast cancer by the same cluster of gene regulation. Furthermore, we predicted and confirmed that Raf-1 is a novel target of both miR-195 and miR-497.
Raf-1 has been found to be overexpressed or overactivated in a variety of cancers, including renal cell carcinoma, hepatocellular carcinoma, non-small cell lung cancer, melanoma, and papillary thyroid carcinoma (32) . Recently, Raf-1 was found to be a target of miR-7 and miR-125b (33) (34) . In breast cancer, miR-125b could target the same region of c-Raf-1 (34) . In addition, Raf-1 was identified as a direct target of miR-7 in several cancer cell lines, including breast cancer (33) . Here, we present the first report that Raf-1 is a direct target of both miR-195 and miR-497 in breast cancer, extending the potential target network of miRNAs. It would be interesting to test whether this novel regulation mechanism of miR-195 and miR-497 in breast cancer, and their common target of Raf-1 may also be extended to other human cancers.
Finally, our data showed that expression levels of miR-195 and miR-497 correlated inversely with malignancy of human breast tumors. Such expression pattern could potentially identify malignant tumors from normal or benign tumors. Recent finding in miRNA study suggests some miRNAs to be used for diagnosis or prognosis of breast cancer in the future. MiR-21 was significantly correlated with advanced clinical stage, lymph node metastasis, and poor survival of the patients (35) . As miRNAs have unique expression profile in cancer tissues, and their expression is more stable than mRNA. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on February 24, 2011; DOI: 10.1158/1078-0432.CCR-10-1800 silence is caused by DNA methylation. Our data imply that miR-195/497 may be potential therapeutic targets in breast cancer therapy. 
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